ONCOPEPTIDES AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.955 SEK | +2.25% |
|
-26.12% | -61.42% |
| Apr. 15 | Oncopeptides AB Secures National Reimbursement for Pepaxti in Spain | CI |
| Apr. 04 | Oncopeptides AB Provides Sales Guidance for the First Quarter of 2024 | CI |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 5,794 | 7,032 | 11,529 | 632.5 | 1,146 | 291.8 | 291.8 | - |
| Enterprise Value (EV) 1 | 5,418 | 6,106 | 10,689 | 441.7 | 801.3 | 657.7 | 84.16 | 233 |
| P/E ratio | -13.4 x | -8.86 x | -6.64 x | -0.44 x | -2.96 x | -2.78 x | -1.94 x | -2.83 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | 5.35 x | 137 x | 20.6 x | 2.78 x | 1.49 x |
| EV / Revenue | - | - | - | 3.73 x | 95.9 x | 18.7 x | 0.8 x | 1.19 x |
| EV / EBITDA | -12.9 x | -8.31 x | -6.78 x | -0.32 x | -2.41 x | -0.76 x | -0.29 x | -0.96 x |
| EV / FCF | -16.2 x | -8.81 x | -8.12 x | -0.29 x | -1.89 x | -2.35 x | -0.35 x | -1.21 x |
| FCF Yield | -6.18% | -11.4% | -12.3% | -343% | -52.8% | -42.5% | -287% | -82.4% |
| Price to Book | 18.3 x | 8.82 x | 20 x | 3 x | 3.73 x | 12.2 x | 1.14 x | 2.71 x |
| Nbr of stocks (in thousands) | 44,092 | 55,413 | 67,940 | 75,292 | 94,309 | 98,761 | 98,761 | - |
| Reference price 2 | 131.4 | 126.9 | 169.7 | 8.400 | 12.15 | 2.955 | 2.955 | 2.955 |
| Announcement Date | 2/22/19 | 2/20/20 | 2/18/21 | 2/17/22 | 2/16/23 | 2/24/24 | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | 118.3 | 8.355 | 35.2 | 105.1 | 195.7 |
| EBITDA 1 | -419 | -734.9 | -1,577 | -1,400 | -332.2 | -241 | -286 | -243 |
| EBIT 1 | -419.3 | -739.4 | -1,591 | -1,421 | -349.4 | -253.4 | -237.7 | -167.1 |
| Operating Margin | - | - | - | -1,201.16% | -4,181.33% | -719.89% | -226.2% | -85.38% |
| Earnings before Tax (EBT) 1 | -419.3 | -739.9 | -1,592 | -1,421 | -337.7 | -248.4 | -244.3 | -177.5 |
| Net income 1 | -419.4 | -740.7 | -1,595 | -1,430 | -338 | -249.1 | -244.3 | -173.7 |
| Net margin | - | - | - | -1,209.11% | -4,044.9% | -707.7% | -232.55% | -88.72% |
| EPS 2 | -9.770 | -14.33 | -25.57 | -19.00 | -4.110 | -2.760 | -1.526 | -1.044 |
| Free Cash Flow 1 | -334.6 | -693.2 | -1,317 | -1,517 | -423 | -279.6 | -241.5 | -192 |
| FCF margin | - | - | - | -1,282.16% | -5,063.03% | -794.34% | -229.85% | -98.09% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 2/22/19 | 2/20/20 | 2/18/21 | 2/17/22 | 2/16/23 | 2/24/24 | - | - |
1SEK in Million2SEK
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q2 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 |
|---|---|---|---|---|---|---|
| Net sales 1 | 66.37 | 54.28 | -21.71 | - | 8.753 | - |
| EBITDA | - | - | - | - | - | - |
| EBIT 1 | -344.8 | -338.9 | -389.8 | -98.86 | -61.09 | -88.85 |
| Operating Margin | -519.53% | -624.43% | 1,795.65% | - | -697.89% | - |
| Earnings before Tax (EBT) 1 | -345.5 | -338.6 | -389.5 | -98.6 | -59.55 | -88.33 |
| Net income 1 | -24.12 | -777.5 | -394 | -98.59 | -59.83 | -88.44 |
| Net margin | -36.33% | -1,432.58% | 1,814.79% | - | -683.5% | - |
| EPS 2 | -0.3200 | -10.33 | -5.230 | -1.310 | -0.7900 | -1.000 |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 8/19/21 | 11/24/21 | 2/17/22 | 5/4/22 | 8/11/22 | 11/9/22 |
1SEK in Million2SEK
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 376 | 926 | 840 | 191 | 345 | 66.9 | 208 | 58.8 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -335 | -693 | -1,317 | -1,517 | -423 | -280 | -242 | -192 |
| ROE (net income / shareholders' equity) | -114% | -139% | -232% | -363% | -134% | -142% | -154% | -81.6% |
| ROA (Net income/ Total Assets) | -90.8% | -107% | -164% | -206% | -82% | -79.9% | - | - |
| Assets 1 | 462.2 | 693.6 | 970.1 | 693.1 | 412.3 | 311.9 | - | - |
| Book Value Per Share 2 | 7.160 | 14.40 | 8.490 | 2.800 | 3.260 | 0.6300 | 2.600 | 1.090 |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex 1 | 0.91 | 2.63 | 20.1 | 0.34 | 2.51 | 0.12 | 10.5 | 6.47 |
| Capex / Sales | - | - | - | 0.29% | 30.01% | 0.33% | 9.96% | 3.3% |
| Announcement Date | 2/22/19 | 2/20/20 | 2/18/21 | 2/17/22 | 2/16/23 | 2/24/24 | - | - |
1SEK in Million2SEK
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
C+
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -61.42% | 26.62M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.74B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- ONCO Stock
- Financials Oncopeptides AB
